Microsoft Corporation (NASDAQ:MSFT) is one of the best software infrastructure stocks to invest in. On June 26, Antigen ...

Antigen Security, LLC ("Antigen") today announced a new partner program with Microsoft, affirming Antigen as one of Microsoft ...

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like ...

The government stated the percentage of zero-dose children in India has actually declined to 0.06 per cent in 2024 from 0.11 ...

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

Specifically, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) program requirements from two BCMA-directed CAR T-cell therapies for multiple myeloma — ciltacabtagene autoleucel ...

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and ...

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

Three major Mount Sinai research studies offer new hope for patients facing chronic lymphocytic leukemia (CLL), a rare type ...

US FDA eliminates REMS for autologous chimeric antigen receptor CAR T cell immunotherapies: Maryland Monday, June 30, 2025, 13:00 Hrs [IST] The US Food and Drug Administration (FD ...

Michael Green, PhD, discusses a new method of assessing lymphoma subtypes utilizing the tumor microenvironment.